Aadi Bioscience Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AADI Nasdaq 2834 https://aadibio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aadi Bioscience Inc

Aadi Bioscience Announces Presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting - May 25th, 2023 9:30 pm
Aadi Bioscience to Participate in Upcoming Investor Events - May 23rd, 2023 12:00 pm
Aadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial - May 10th, 2023 12:00 pm
Aadi Bioscience to Report First Quarter 2023 Results and Operational Update - May 3rd, 2023 12:00 pm
Aadi Bioscience Announces Multiple Presentations on nab-Sirolimus at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting - Apr 26th, 2023 8:05 pm
Aadi Bioscience to Present Multiple Posters on nab-Sirolimus at the 2023 American Association for Cancer Research (AACR) Annual Meeting - Apr 14th, 2023 5:00 pm
Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2023 - Apr 6th, 2023 8:30 pm
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Corporate Update - Mar 28th, 2023 12:00 pm
Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of Directors - Mar 27th, 2023 12:00 pm
Aadi Bioscience Presents Clinical Data from PRECISION 1 and AMPECT Trials at the Society of Gynecological Oncology (SGO) Annual Meeting on Women's Cancer - Mar 26th, 2023 6:00 pm
Aadi Bioscience to Report Fourth Quarter and Full-Year 2022 Results and Corporate Update - Mar 15th, 2023 12:00 pm
Aadi Bioscience Announces Leadership Transition - Mar 3rd, 2023 1:00 pm
Aadi Bioscience to Present at the 43rd Annual Cowen Healthcare Conference - Feb 22nd, 2023 1:00 pm
Aadi Bioscience Presents PRECISION 1 Trial in Progress Poster and AMPECT Trial Final Analysis at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting - Nov 17th, 2022 1:00 pm
Aadi Bioscience Announces Financial Results for the Third Quarter of 2022 and Provides Corporate Update - Nov 9th, 2022 1:00 pm
Aadi Bioscience Announces Planned Leadership Transition - Nov 8th, 2022 9:00 pm
Aadi Bioscience to Present at Upcoming Investor Conferences - Nov 3rd, 2022 12:00 pm
Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium - Oct 27th, 2022 12:00 pm
Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C] Mutation - Oct 12th, 2022 12:00 pm
Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing - Sep 22nd, 2022 8:01 pm